EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort

Camilla Nero, Rita Trozzi iD, Federica Persiani, Simone Rossi, Luca Mastrantoni, Simona Duranti iD, Floriana Camarda, Ilenia Marino, Luciano Giacò iD, Tina Pasciuto, Maria De Bonis, Martina Rinelli und 8 weitere

Cancer · 2025-02 · 131 (3)

DOI: 10.1002/cncr.35731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 25.01.2025. Verfasst von Camilla Nero und 19 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Oncological Gynecology, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, DNA Polymerase II, Poly-ADP-Ribose Binding Proteins, Mutation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To date, 11 DNA polymerase epsilon ( POLE ) pathogenic variants have been declared “hotspot” mutations. Patients with endometrial cancer (EC) characterized by POLE hotspot mutations ( POLE mut) have exceptional survival outcomes. Whereas international guidelines encourage deescalation of adjuvant treatment in early‐stage POLE mut EC, data regarding safety in POLE mut patients with unfavorable characteristics are still under investigation. On the other hand, the spread of comprehensive genome profiling programs has underscored the need to interpret POLE variants not considered to be hotspots.

Methods

This study provides a comprehensive analysis of 596 sequenced patients with EC. The genomic landscape of POLE mut EC was compared with cases harboring nonhotspot POLE mutations within the exonuclease domain. Additionally, the genomic characteristics of multiple classifiers, as well as those exhibiting unfavorable histopathological and clinical features, were examined.

Results

No significant genomic differences were observed among patients with POLE mut EC when comparing multiple classifiers to not‐multiple classifiers or those with unfavorable clinical features. However, the tumor mutational burden differed in both comparisons, whereas the percentage of C>G mutations only differed in the comparison based on clinical features. Specific POLE mutations, even if not considered to be hotspots, have genomic features comparable to POLE mut.

Conclusions

The present findings confirm the absence of significant genomic differences among POLE mut patients regardless of multiple‐classifier status or association with high‐risk clinical features. Prognostic data will be essential to elucidate the clinical significance of POLE mutations not classified as hotspots that exhibit genomic characteristics similar to those in POLE mut patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsDNA Polymerase IIPoly-ADP-Ribose Binding ProteinsMutationHumansFemaleMiddle AgedAgedProspective StudiesGenomicsAdultAged, 80 and overPrognosis

Stichwörter der Autor:innen

DNA polymerase epsilon (POLE)POLE hotspotsPOLE multiclassifieradjuvant therapycomprehensive genomic profilingendometrial cancermolecular classification

Substanzen

DNA Polymerase IIPOLE protein, humanPoly-ADP-Ribose Binding Proteins

Autor:innen und Institutionen

  • Unit of Oncological Gynecology, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Università Cattolica del Sacro Cuore, Rome, Italy.
  • Bioinformatics Research Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • European School of Molecular Medicine (SEMM), Milan, Italy.
  • University of Milan, Milan, Italy.
  • Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.

ORCID-Profile: Rita Trozzi, Simona Duranti, Luciano Giacò, Giovanni Scambia

Förderung

  • Italian Ministry of Health

Zitieren

APA

Nero, C., Trozzi, R., Persiani, F., Rossi, S., Mastrantoni, L., Duranti, S., Camarda, F., Marino, I., Giacò, L., Pasciuto, T., De Bonis, M., Rinelli, M., Perrone, E., Giacomini, F., Lorusso, D., Piermattei, A., Zannoni, G., Fanfani, F., Scambia, G., & Minucci, A. (2025). POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort. Cancer, 131(3). https://doi.org/10.1002/cncr.35731

Vancouver

Nero C, Trozzi R, Persiani F, Rossi S, Mastrantoni L, Duranti S, et al. POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort. Cancer. 2025;131(3). doi:10.1002/cncr.35731

BibTeX
@article{Nero2025,
  author = {Nero, Camilla and Trozzi, Rita and Persiani, Federica and Rossi, Simone and Mastrantoni, Luca and Duranti, Simona and Camarda, Floriana and Marino, Ilenia and Giacò, Luciano and Pasciuto, Tina and De Bonis, Maria and Rinelli, Martina and Perrone, Emanuele and Giacomini, Flavia and Lorusso, Domenica and Piermattei, Alessia and Zannoni, Gianfranco and Fanfani, Francesco and Scambia, Giovanni and Minucci, Angelo},
  title = {POLE mutations in endometrial carcinoma: Clinical and genomic landscape from a large prospective single‐center cohort},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {3},
  doi = {10.1002/cncr.35731}
}
Kostenlos starten →